Such findings of association with reproductive hormones are supported by several earlier studies showing that FGFR2 variants contribute to breast cancer and confer their effect primarily in ER-positive and PR-positive tumor subtypes [42], [44], [46], [60], [61]. This evidence concerns the gene ESR1 and breast cancer.